“Pay as little as $25, subject to a maximum savings of $100/month.”
“Patients pay $149 for each month of 1.5 mg, and $199 per month for 4 mg and $299 per month for 9 mg and 25 mg.”
From the maker’s offer on wegovy.com, checked November 17, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Maker’s card or discount card?
A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s price above. You can usually use one or the other on a fill, not both.
Authorized generic
There isn’t one.
Not soldThere isn’t one
Regular generic
No generic is sold yet.
Not soldNone sold yet
Coverage: Medicare and many other plans cover weight-loss drugs only in some cases. Ask your plan.
WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist.
WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity:
to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
to reduce excess body weight and maintain weight reduction long term in:
oadults and pediatric patients aged 12 years and older with obesity.
oadults with overweight in the presence of at least one weight-related comorbid condition.
for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.
WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity:
to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.
Limitations of Use:
Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.
Source: the FDA label for Wegovy (Novo Nordisk Pharmaceutical Industries, LP), June 18, 2026. Full label on DailyMed
Good to know
“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.
Prices checked November 17, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/wegovy/